BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 19887503)

  • 1. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
    Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension after kidney transplantation: still a SECRET?
    Lopau K; Wanner C
    Nephrol Dial Transplant; 2010 Mar; 25(3):664-5. PubMed ID: 20042402
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
    Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
    Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.
    Okumi M; Kawada N; Ichimaru N; Kitamura H; Abe T; Imamura R; Kojima Y; Kokado Y; Isaka Y; Rakugi H; Nonomura N; Moriyama T; Takahara S
    Clin Exp Nephrol; 2011 Dec; 15(6):907-15. PubMed ID: 21818547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
    Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
    J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
    Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
    J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G; Schmieder R; Calvo C; Asmar R
    Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
    Asmar R; Porcellati C; Dusing R
    Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
    J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
    Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term renoprotective effect of candesartan in renal transplant patients.
    Ishii T; Yasuda M; Itami Y; Hayashi T; Uemura H; Nose K; Nishioka T
    Transplant Proc; 2012 Apr; 44(3):638-41. PubMed ID: 22483458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R; Mugellini A; Derosa G;
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P; Fairley KF; Packham D
    Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R; Mashavi M; Zimlichman R
    Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.